Gladiolin produced by pathogenic Burkholderia synergizes with amphotericin B through membrane lipid rearrangements
mBio · 13.11.2024 · 15 (11)
DOI: 10.1128/mbio.02611-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 13.11.2024. Verfasst von Claudia Simm und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology and the Infection Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Au…. Hauptthemen laut MEDLINE: Amphotericin B, Drug Synergism, Antifungal Agents, Membrane Lipids. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Education and Training | Australian Research Council (ARC), University of Exeter, NIHR Exeter Biomedical Research Centre.
Abstract (Originalsprache)
Amphotericin B (AmpB) is an effective but toxic antifungal drug. Thus, improving its activity/toxicity relationship is of interest. AmpB disrupts fungal membranes by two proposed mechanisms: ergosterol sequestration from the membrane and pore formation. Whether these two mechanisms operate in conjunction and how they could be potentiated remains to be fully understood. Here, we report that gladiolin, a polyketide antibiotic produced by Burkholderia gladioli , is a strong potentiator of AmpB and acts synergistically against Cryptococcus and Candida species, including drug-resistant C. auris . Gladiolin also synergizes with AmpB against drug-resistant fungal biofilms, while exerting no mammalian cytotoxicity. To explain the mechanism of synergy, we show that gladiolin interacts with membranes via a previously unreported binding mode for polyketides. Moreover, gladiolin modulates lipid binding by AmpB and, in combination, causes faster and more pronounced lipid rearrangements relative to AmpB alone which include membrane thinning consistent with ergosterol extraction, areas of thickening, pore formation, and increased membrane destruction. These biophysical data provide evidence of a functional interaction between gladiolin and AmpB at the membrane interface. The data further indicate that the two proposed AmpB mechanisms (ergosterol sequestration and pore formation) act in conjunction to disrupt membranes, and that gladiolin synergizes by enhancing both mechanisms. Collectively, our findings shed light on AmpB’s mechanism of action and characterize gladiolin as an AmpB potentiator, showing an antifungal mechanism distinct from its proposed antibiotic activity. We shed light on the synergistic mechanism at the membrane, and provide insights into potentiation strategies to improve AmpB’s activity/toxicity relationship. IMPORTANCE Amphotericin B (AmpB) is one of the oldest antifungal drugs in clinical use. It is an effective therapeutic, but it comes with toxicity issues due to the similarities between its fungal target (the membrane lipid ergosterol) and its mammalian counterpart (cholesterol). One strategy to improve its activity/toxicity relationship is by combinatorial therapy with potentiators, which would enable a lower therapeutic dose of AmpB. Here, we report on the discovery of the antibiotic gladiolin as a potentiator of AmpB against several priority human fungal pathogens and fungal biofilms, with no increased toxicity against mammalian cells. We show that gladiolin potentiates AmpB by increasing and accelerating membrane damage. Our findings also provide insights into the on-going debate about the mechanism of action of AmpB by indicating that both proposed mechanisms, extraction of ergosterol from membranes and pore formation, are potentiated by gladiolin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology and the Infection Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
- Centre to Impact AMR, Monash University, Clayton, Victoria, Australia.
- School of Life Sciences, University of Warwick, Coventry, United Kingdom.
- Department of Chemistry, University of Warwick, Coventry, United Kingdom.
- School of Medicine, Monash University, Clayton, Victoria, Australia.
- Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom.
ORCID-Profile: Claudia Simm, Dean Walsh, Rebecca Inman, Freya Harrison, Marie-Isabel Aguilar, Gregory L Challis, Ana Traven
Förderung
- Department of Education and Training | Australian Research Council (ARC)
- University of Exeter
- NIHR Exeter Biomedical Research Centre
- UKRI | Biotechnology and Biological Sciences Research Council (BBSRC)
- University of Warwick (Warwick)
- DHAC | National Health and Medical Research Council (NHMRC)
- Monash-Warwick Alliance
- Medical Research Council
Zitieren
APA
Simm, C., Lee, T. H., Weerasinghe, H., Walsh, D., Nakou, I. T., Shankar, M., Tse, W. C., Zhang, Y., Inman, R., Mulder, R. J., Harrison, F., Aguilar, M. I., Challis, G. L., & Traven, A. (2024). Gladiolin produced by pathogenic Burkholderia synergizes with amphotericin B through membrane lipid rearrangements. mBio, 15(11). https://doi.org/10.1128/mbio.02611-24
Vancouver
Simm C, Lee TH, Weerasinghe H, Walsh D, Nakou IT, Shankar M, et al. Gladiolin produced by pathogenic Burkholderia synergizes with amphotericin B through membrane lipid rearrangements. mBio. 2024;15(11). doi:10.1128/mbio.02611-24
BibTeX
@article{Simm2024,
author = {Simm, Claudia and Lee, Tzong-Hsien and Weerasinghe, Harshini and Walsh, Dean and Nakou, Ioanna T and Shankar, Madhu and Tse, Wai Chung and Zhang, Yu and Inman, Rebecca and Mulder, Roger J and Harrison, Freya and Aguilar, Marie-Isabel and Challis, Gregory L and Traven, Ana},
title = {Gladiolin produced by pathogenic Burkholderia synergizes with amphotericin B through membrane lipid rearrangements},
journal = {mBio},
year = {2024},
volume = {15},
number = {11},
doi = {10.1128/mbio.02611-24}
}
EUVIMED